TLDR
- JNJ hit an all-time high of $251.76 on June 26, 2026, with a 1-year total return of 65.12%
- Guggenheim raised its price target to $270 from $266, keeping a Buy rating and naming JNJ a top large-cap biopharma pick
- Q2 2026 earnings are due July 15; Guggenheim forecasts revenue of $25.48B and EPS of $2.87, above consensus
- Strong prescription trends for Tremfya, Caplyta, and Erleada drove the price target increase
- A Los Angeles jury awarded $32 million against JNJ in a talc-related mesothelioma case
Johnson & Johnson stock touched a fresh all-time high of $251.76 on Thursday, June 26, before pulling back slightly to trade around $251.18 — still just 0.97% below that peak. The move puts JNJ’s 1-year total return at 65.12%, with a market cap of $604.8 billion.
The rally comes the same day Guggenheim lifted its price target on JNJ to $270, up from $266, while holding its Buy rating. The firm also named JNJ a top pick among large-cap biopharmaceutical companies.
Guggenheim is penciling in Q2 2026 revenues of $25.48 billion and earnings per share of $2.87. Both figures sit above the current Wall Street consensus of $24.96 billion in revenue and $2.85 EPS.
What’s Driving the Upgrade
The price target increase was fueled by stronger-than-expected prescription trends for three key drugs: Tremfya, Caplyta, and Erleada. All three came in ahead of Guggenheim’s internal estimates.
The firm flagged that prescription data for two newer launches — Icotyde and Inlexzo — are not yet reliable enough to factor in. Analysts will be watching those closely once data matures.
Guggenheim expects the earnings call on July 15 to center on Tremfya volume growth, the Icotyde launch, the multiple myeloma portfolio, Caplyta, and Spravato.
JNJ has raised its dividend for 55 consecutive years, which continues to make it a go-to name for income-focused investors.
Recent Business Developments
Away from the stock, JNJ announced an investment of more than $1 billion into its Jacksonville, Florida operations. The money is earmarked for expanding manufacturing, packaging, and distribution capacity for its Vision business, with a focus on ACUVUE contact lenses.
The company also expanded U.S. availability of its TECNIS PureSee intraocular lens, used in cataract surgery. On the clinical side, JNJ reported positive Phase 2/3 results for Imaavy in patients with warm autoimmune hemolytic anemia.
Not everything is smooth sailing. A Los Angeles jury found JNJ liable for mesothelioma in the case of Maria Lozano, awarding her family $32 million. The case ties back to asbestos-contaminated talc in JNJ’s baby powder — a legal overhang the company has dealt with for years.
InvestingPro analysis currently flags the stock as slightly overvalued at these levels, even with the strong momentum behind it.
🚨 Our JUNE Stock Picks Are Live!
A new month means new opportunities. Our analysts have just released their top stock picks for June, highlighting companies with strong momentum that rank highly on our KO Score algorithm. We’re also now sharing trade ideas for both long-term and short-term investors, giving you more ways to spot potential opportunities in the market.
Sign up to Knockout Stocks today and get 50% off to unlock the full list and see which stocks made the cut.
Use coupon code Special50 for your exclusive discount!
